• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aquestive Therapeutics Inc.

    1/24/25 4:51:09 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AQST alert in real time by email
    S-8 1 g122252s8.htm

     

    As filed with the Securities and Exchange Commission on January 24, 2025

     

    Registration No. 333-_______

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Aquestive Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    30 Technology Drive

    Warren, NJ 07059

    82-3827296
    (State or Other Jurisdiction of
    Incorporation or Organization)

    (Address of Principal Executive
    Offices)

    (Zip Code)

    (I.R.S. Employer Identification No.)

     

    Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended

    (Full title of the plan)

     

    A. Ernest Toth, Jr.

    Chief Financial Officer

    Aquestive Therapeutics, Inc.

    30 Technology Drive

    Warren, NJ 07059

    (Name and address of agent for service)

     

    (908) 941-1900

    (Telephone number, including area code, of agent for service)

     

    Copies of all communications to:

    Lori J. Braender

    Chief Legal Officer and Corporate Secretary

    Aquestive Therapeutics, Inc.

    30 Technology Drive

    Warren, NJ 07059

    908-941-1900

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  o Accelerated filer  o
    Non-accelerated filer  ý Smaller reporting company  ý
      Emerging growth company o

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

     

     

      
     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed by Aquestive Therapeutics, Inc. (the “Registrant”) for the purpose of registering an additional 3,656,549 shares of common stock, par value $0.001 per share (the “Common Stock”), of the Registrant available for issuance under the Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended (the “2018 Plan”), pursuant to provisions of the 2018 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan. The Registrant previously filed with the Securities and Exchange Commission (the “Commission”) registration statements on Form S-8 on July 27, 2018 (File No. 333-226399), January 8, 2021 (File No. 333-251984), January 7, 2022 (File No. 333-262051), January 18, 2023 (File No. 333-269292), August 9, 2023 (File No. 333-273857), and February 12, 2024 (File No. 333-277015) (collectively, the “Prior Registration Statements”) registering shares of Common Stock issuable under the 2018 Plan. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by this Registration Statement below.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, as originally filed with the Commission by the Registrant, are incorporated herein by reference; provided, however, that any reports or portions thereof that are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items, shall not be deemed incorporated by reference in this Registration Statement:

     

    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 5, 2024;

     

    (b)The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the Commission on May 7, 2024;

     

    (c)The Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the Commission on August 6, 2024;

     

    (d)The Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Commission on November 4, 2024;

     

    (e)The Registrant’s Current Reports on Form 8-K, filed with the Commission on March 15, 2024, March 21, 2024, April 1, 2024, April 22, 2024, April 29, 2024, June 6, 2024, June 21, 2024, July 25, 2024, August 14, 2024, September 27, 2024, October 16, 2024, October 24, 2024, October 25, 2024, November 7, 2024, December 2, 2024, and December 19, 2024; and

     

    (f)The description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-38599) filed with the Commission on July 20, 2018, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by the description of the Common Stock contained in Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Commission on March 11, 2020, including any amendment or report filed for the purpose of updating such description.

     

      
     

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference from the date of filing of such documents; provided, however, that any reports or portions thereof that are furnished, including under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items, shall not be deemed incorporated by reference in this Registration Statement. Any statement contained herein or in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for all purposes to the extent that a statement contained in this Registration Statement or in any other subsequently filed document which is incorporated by reference herein modifies or replaces such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    Exhibit Number Description of Exhibit
       
    4.1 Aquestive Therapeutics, Inc. 2018 Equity Incentive Plan, as amended (filed as Exhibit 4.1 to the Registration Statement on Form S-8 of the Registrant (File No. 333-273857), as filed on August 9, 2023 and incorporated by reference herein).
       
    5.1 Legal Opinion of Lori J. Braender, Chief Legal Officer and Corporate Secretary, filed herewith.
       
    23.1 Consent of KPMG LLP, filed herewith.
       
    24.1 Powers of Attorney, filed herewith (included on the signature page of this Registration Statement under the caption “Power of Attorney”).
       
    107 Filing Fee Table, filed herewith.

     

      
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey, on this 24th day of January, 2025.

     

      AQUESTIVE THERAPEUTICS, INC.
       
      By: /s/ Daniel R. Barber
      Name: Daniel R. Barber
      Title: President and Chief Executive Officer

     

     

     

     

     

     

    Get the next $AQST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQST

    DatePrice TargetRatingAnalyst
    6/2/2025$7.00Outperform
    Oppenheimer
    12/17/2024$17.00Overweight
    Cantor Fitzgerald
    5/10/2024$8.00Outperform
    Leerink Partners
    4/11/2024$10.00Overweight
    Piper Sandler
    3/28/2024$7.00Outperform
    Raymond James
    More analyst ratings

    $AQST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Officer Boyd Peter E. was granted 20,000 shares, increasing direct ownership by 7% to 288,323 units (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    12/5/25 1:06:06 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Regulatory Affairs Cioffi Melina covered exercise/tax liability with 2,083 shares, decreasing direct ownership by 1% to 200,178 units (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    12/4/25 10:39:37 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Davis Matthew W. was granted 50,000 shares (SEC Form 4)

    4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

    11/12/25 9:35:57 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    SEC Filings

    View All

    SEC Form 144 filed by Aquestive Therapeutics Inc.

    144 - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    11/17/25 4:39:52 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    11/6/25 4:01:52 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Aquestive Therapeutics Inc.

    10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)

    11/5/25 4:07:03 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

    WARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference December 2-4, 2025, in New York City. The Aquestive team will hold a fireside chat with Piper Sandler Sr. Research Analyst David Amsellem on December 4, 2025, at 10:00 a.m. ET. The discussion will focus on the Company's product candidate Anaphylm™ (dibutepinephrine) sublingual film, includin

    11/24/25 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened balance sheet to support planned commercial launch execution of AnaphylmCompany to host investor call on November 6, 2025, at 8:00am ET WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the third quarter ended September 30, 2

    11/5/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Announces Leadership Expansion to Support Growth

    Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company's ongoing development initiatives Matthew Davis, M.D., RPh will join immediately as Chief Development OfficerGary Slatko, M.D., M.B.A, will become interim Chief Medical Officer Peter Boyd, M.B.A, has been promoted to Chief People Officer WARREN, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced changes to

    11/4/25 7:00:00 AM ET
    $AQST
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Financials

    Live finance-specific insights

    View All

    Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened balance sheet to support planned commercial launch execution of AnaphylmCompany to host investor call on November 6, 2025, at 8:00am ET WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the third quarter ended September 30, 2

    11/5/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

    WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2025 and provide an update on recent developments in its business after market close on Wednesday, November 5, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, November 6, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A liv

    10/27/25 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany to host investor call on August 12, 2025, at 8:00am ET WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update. "The sec

    8/11/25 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Leadership Updates

    Live Leadership Updates

    View All

    Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

    WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public

    6/18/24 8:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

    WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

    4/1/24 8:00:00 AM ET
    $AQST
    $EBS
    $GMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

    Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N

    6/29/23 8:42:55 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aquestive Therapeutics Inc.

    SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    11/14/24 3:47:19 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    4/1/24 6:21:14 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aquestive Therapeutics Inc.

    SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

    2/14/24 3:24:42 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Aquestive Therapeutics with a new price target

    Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00

    6/2/25 8:47:02 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Aquestive Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00

    12/17/24 7:27:23 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Aquestive Therapeutics with a new price target

    Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/10/24 7:29:48 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care